Key points are not available for this paper at this time.
From QualityMetric, Inc.; Lincoln, Rhode Island; and the Health Assessment Lab; Tufts Medical School, and Harvard School of Public Health, Boston, Massachusetts. Address reprint requests to John E. Ware, Jr., PhD QualityMetric, Inc. 640 George Washington Highway Lincoln, RI 02865 E-mail: email protected Development and validation of the SF-36 Health Survey was supported by a grant from the Henry J. Kaiser Family Foundation to The Health Institute, New England Medical Center (J. E. Ware, Jr., Principal Investigator). Development of the SF-36 PCS and MCS summary measures was supported by unrestricted research grants for the International Quality of Life Assessment (IQOLA) Project for the Glaxo Research Institute, Research Triangle Park, NC and Schering-Plough Corp., Kenilworth, NJ (J. E. Ware, Jr., Principal Investigator). The IQOLA Project is sponsored by unrestricted research grants from GlaxoWellcome Inc., Research Triangle Park, NC, and Schering-Plough Corp., Kenilworth, NJ. Associate sponsors include Astra, Parke-Davis, Pharmacia & Upjohn, Proctor & Gamble Pharmaceuticals, Searle, Solvay Duphar B.V., and Synthelabo. Additional support has also been provided by more than 40 other pharmaceutical companies.
John E. Ware (2000) studied this question.